112 Results Cohort description Demographic and clinical characteristics (IBD: n = 497; population controls: n = 1,326) are presented in Table 1. In total, 497 patients were included: 256 diagnosed with CD, 207 with UC and the remaining 34 patients with an undetermined type of IBD (IBD-U). A schematic overview of the study workflow is presented in Figure 1. Table 1 | Demographic and clinical characteristics of the study population (IBD: n = 497). Chapter 4 Table 1. Demographic and clinical characteristics of the study population (IBD: n = 497). Variable Total CD UC P-value n = 497 n = 256 n = 207 Age (years) 39 [28;53] 35 [26;46] 44 [34;54] <0.001 Female sex, n (%) 312 (62.8) 181 (70.7) 116 (56.0) 0.001 BMI (kg/m2) 24.7 [21.7-28.1] 23.7 [21.2;27.6] 25.3 [22.3;29.0] 0.001 IBD diagnosis, n (%) 497 (100) - CD 256 (51.5) 256 (100) - UC 207 (41.6) - 207 (100) IBD-U 34 (6.9) - - Disease duration (years) 8.1 [3.5-15.2] 8.2 [3.1;15.0] 8.2 [4.4;15.4] 0.642 Current smoking, n (%) 497 (100) 256 (100) 207 (100) <0.001 Yes 108 (21.7) 80 (31.3) 24 (11.6) No 389 (78.3) 176 (68.8) 183 (88.4) Montreal classification Montreal Age (A), n (%) 496 (99.8) 255 (99.6) 207 (100) <0.001 A1 (≤16 years) 66 (13.3) 42 (16.5) 20 (9.7) A2 (17-40 years) 326 (65.6) 179 (70.2) 127 (61.4) A3 (>40 years) 104 (20.9) 34 (13.3) 60 (29.0) Montreal Location (L), n (%) - 252 (98.4) - L1 (ileal disease) - 69 (27.4) - L2 (colonic disease) - 58 (23.0) - L3 (ileocolonic disease) - 102 (40.5) - L4 (upper GI disease) - 5 (2.0) - L1 + L4 - 8 (3.2) - L2 + L4 - 4 (1.6) - L3 + L4 - 6 (2.4) - Montreal Behavior (B), n (%) - 253 (98.8) - B1 (non-stricturing, nonpenetrating) - 109 (43.1) - B2 (stricturing) - 49 (19.4) - B3 (penetrating) - 19 (7.5) - B1 + P (perianal disease) - 31 (12.3) - B2 + P (perianal disease) - 13 (5.1) - B3 + P (perianal disease) - 0 (0.0) - Montreal Extension (E), n (%) - - 207 (100) E1 (proctitis) - - 26 (12.6) E2 (left-sided colitis) - - 63 (30.4) E3 (pancolitis) - - 118 (57.0) Medication use, n (%) 496 (99.8) 255 (99.6) 207 (100) Aminosalicylates 193 (38.8) 27 (10.6) 143 (69.1) <0.001 Thiopurines 189 (38.0) 113 (44.3) 68 (32.9) 0.012 Steroids 119 (23.9) 61 (23.9) 49 (23.7) 0.950 Calcineurin inhibitors 8 (1.6) 1 (0.4) 7 (3.4) 0.025 Methotrexate 38 (7.6) 31 (12.2) 4 (1.9) <0.001 TNF-α-antagonists† 120 (24.1) 98 (38.4) 18 (8.7) <0.001 Disease activity score 355 (71.4)
RkJQdWJsaXNoZXIy MjY0ODMw